

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 January 2022 (20.01.2022)




(10) International Publication Number
WO 2022/013286 A1

- (51) International Patent Classification:
G01N 33/68 (2006.01)
- (21) International Application Number:
PCT/EP2021/069595
- (22) International Filing Date:
14 July 2021 (14.07.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/705,759 14 July 2020 (14.07.2020) US
63/200,399 04 March 2021 (04.03.2021) US
- (71) Applicant: **JANSSEN PHARMACEUTICA NV**
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).
- (72) Inventors: **KOLB, Hartmuth C.**; Janssen R&D, 3210 Merryfield Row, San Diego, CA 92121 (US). **TRIANA-BALTZER, Gallen**; Janssen R&D, 3210 Merryfield Row, San Diego, California 92121 (US). **SAAD, Ziad**; Janssen R&D, 3210 Merryfield Row, San Diego, California 92121 (US).
- (74) Agent: **DUFFIELD, Stephen** et al.; Carpmacels & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH,

(54) Title: BLOOD-BASED ASSAY FOR DETECTING TAUOPATHY OR AMYLOIDOGENIC DISEASE

FIG. 5B

Plasma p217+Tau
Revised Assay: 02Dec2019



(57) **Abstract:** A method for detecting p217+tau in blood-based samples from a subject with high sensitivity, accuracy, and precision. The assay comprises contacting a sample with a capture antibody directed against a p217+tau epitope to bind the capture antibody to p217+tau peptides in plasma to form antibody-peptide complexes, and separately contacting the antibody-peptide complexes with a detection antibody to bind the detection antibody to the antibody-peptide complexes. The amount of p217+tau is determined by detecting the detection antibody. The amount of p217+tau detected is used to determine whether the subject has tauopathy or is at risk of developing tauopathy, or whether the subject has amyloidogenic disease or is at risk of developing amyloidogenic disease when the amount of p217+tau peptides is above a predetermined threshold value. The method has improved sensitivity such that the predetermined threshold value is above a Lower Limit of Quantification and/or Lower Limit of Detection of the assay.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))